1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Easywell Biomedicals, Inc.

Easywell Biomedicals, Inc.

TTPEX:1799
27.70
TWD
-0.50
(-1.77%)
-0.12EPS
3.89BMarket Cap
Easywell Biomedicals, Inc.
TPEX:1799
(Taipei Exchange)

Recent

price

27.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
11.15
4.35
8.22
5.24
6.97
10.67
6.97
6.34
5.99
4.65
2.84
1.89
1.55
2.37
4.5
4.83
6.45
Revenue per Share
-0.29
-4.7
-9.87
-8.66
-3.11
-3.3
-5.42
-4.94
-3.46
-3.51
-1.84
-1.44
-1.39
-1.27
-0.81
-0.59
-0.13
Basic EPS, GAAP
-1.81
-3.32
-6.45
-4.56
-4.87
-6.3
-5.98
-5.09
-4.01
-2.49
-1.86
-1.31
-0.53
-1.49
-1.43
0.88
1.36
Free Cash Flow per Basic Share
1.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
22.21
- -
11.39
9.91
14.76
18.61
15.83
13.63
10.25
7.61
7.14
7.56
6.39
5.23
5.9
5.54
5.69
Book Value per Share
21.39
- -
10.8
9.89
7.94
13.34
8.81
8.34
6.98
5.9
5.72
6
4.93
3.9
4.78
4.73
5.07
Tangible Book Value per Share
17
18
12
19
33
44
47
59
70
77
94
104
116
114
120
124
124
Basic Weighted Avg Shares
194
77
95
100
227
468
328
374
419
360
268
197
179
272
540
597
800
Sales/Revenue/Turnover
-3.97
-115.34
-115.69
-96.74
-36.28
-32.2
-82.52
-87.13
-45.95
-60
-59.35
-107.39
-90.14
-59.91
-12.92
-11.69
-0.65
Operating Margin (%)
19
25
23
21
14
30
59
84
74
88
81
71
67
65
80
91
102
Depreciation Expense
-5
-84
-114
-166
-101
-145
-255
-292
-242
-272
-173
-150
-161
-145
-97
-73
-16
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-2.58
-108.14
-120.09
-165.17
-44.58
-30.94
-77.78
-77.9
-57.77
-75.51
-64.79
-76.23
-90
-53.31
-18.04
-12.24
-1.96
Profit Margin (%)
257
- -
87
120
272
411
404
474
167
163
255
474
348
380
394
422
443
Working Capital
- -
- -
- -
- -
- -
- -
23
99
- -
315
296
316
338
330
342
312
305
LT Debt
395
- -
204
204
618
927
1,076
1,103
794
697
764
912
771
624
739
703
723
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-1.22
-42.34
-111.29
-81.08
-26.4
-20.18
-28.92
-31.65
-29
-38.99
-25.11
-19.07
-19.97
-21.43
-14.64
-10.38
-2.3
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
114
119
82
LT Borrowings
- -
- -
- -
LT Finance Leases
312
312
305
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
125
125
125
Market Capitalization
4,464
4,570
3,890

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
700
719
706
Cash, Cash Equivalents & STI
452
454
485
Accounts Receivable, Net
38
60
27
Inventories
159
159
170
Total Current Liabilities
278
294
264
Payables & Accruals
- -
- -
- -
ST Debt
114
119
82
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.37%
-0.31%
-4.95%
Free Cash Flow
-9.99%
-12.27%
-163.66%
Net Income, GAAP
-2.44%
-14.79%
-24.96%
Sales/Revenue/Turnover
8.21%
25.14%
10.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
73
123
190
154
540
2025
152
109
174
162
597
2026
237
227
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.41
-0.18
-0.05
-0.17
-0.81
2025
- -
-0.39
0.05
-0.24
-0.59
2026
0.16
-0.1
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Easywell Biomedicals, Inc. (1799.TWO) develops, manufactures and sells active pharmaceutical ingredients, over-the-counter drug products, medical devices and regenerative medicine therapies. The company offers digital clinical thermometers; infrared ear thermometers and non-contact forehead thermometers; transcutaneous electrical nerve stimulation (TENS) products for pain relief; in vitro diagnostic devices including meters and test strips; pharmaceuticals encompassing technically challenging generics and 505(b)(2) products such as anti-cough medicine TLX-001, anti-urinary incontinence medicine TLX-005, breast cancer treatment TLX-006 for PMS women, anti-depressants TLX-007 and TLX-004, Parkinson patch TWB-201, urinary medicine TLX-501, pneumonia medicine TLX-502, postpartum hemorrhage treatments TLX-015 and TLX-018, liquid oral epilepsy drug ET-101, sacubitril-valsartan sodium tablets HH-001 (Yuexintuo), neurological disorder treatment TLX-050 and injectable TLX-054; health foods; and regenerative therapies like fetal skin cell product TWB-103 for wound healing. Easywell Biomedicals operates through Drug Development and Other segments, with facilities including a cGMP medical device plant in Shenzhen, China, a cGMP pharmaceutical development and manufacturing site in Cranbury, New Jersey, USA via subsidiary Tulex Pharmaceuticals Inc., and headquarters in Hsinchu Science Park, Taiwan; it serves markets in America, Europe, China and Asia. Incorporated in 1998 as Actherm Inc. and renamed Easywell Biomedicals in July 2015, the company expanded via acquisition of Magnifica Inc. in 2014 for pharmaceutical capabilities and Transwell Biotech Inc. in 2016 for regenerative medicine. Recent developments include a December 2024 collaboration with partners on TLX-050 neurological drug adding a third-party ally; September 2024 update on HH-001 China market expansion; March 2024 launch of subsidiary Jiangsu Huahan's HH-001 sacubitril-valsartan by grandson company; October 2023 NMPA approval for HH-001; May 2023 US FDA Phase II clearance for TLX-032; March 2023 exclusive licensing and CDMO deal with Eton Pharmaceuticals for pediatric rare disease drug; strategic partnership with Formosa Laboratories for TLX-054 injectable; and a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience for TLX-050.